Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Business (Details Narrative)

v3.20.2
Organization and Nature of Business (Details Narrative) - Hanover Portfolio Acquisitions, Inc [Member]
6 Months Ended
Jun. 30, 2020
Acquisitions description On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company's Certificate of Incorporation to change the name of the Company from "Hanover Portfolio Acquisitions, Inc." to "Endonovo Therapeutics, Inc." The name change was affected pursuant to a Certificate of Amendment (the "Certificate of Amendment"), filed with the Secretary of State of Delaware on January 24, 2014.
Common stock, voting rights Common Stock representing in excess of 50% of the total issued and outstanding voting power